Page 4 - Treatment Patterns News Today

Four oral presentations presented at ASH highlight data evaluating investigational epcoritamab for the treatment of relapsed/refractory (R/R) foll...

COPENHAGEN, Denmark--(BUSINESS WIRE)--Epcoritamab featured in multiple data disclosures, including four oral presentationsResults presented from the phase 1b/2 EPCORE™ NHL-2 trial of epcoritamab combined with standard salvage therapy in patients with transplant eligible relapsed/refractory (R/R) diffuse large B-cell...

Epcoritamab featured in multiple data disclosures, including four oral presentations Results presented from the phase 1b/2 EPCORE NHL-2 trial of epcoritamab combined with standard salvage

/PRNewswire/ -- AbbVie (NYSE: ABBV) today announced data from multiple clinical trials evaluating epcoritamab (DuoBody®-CD3xCD20), an investigational...

/PRNewswire/ -- AbbVie (NYSE: ABBV) will present results from nearly 65 company and partner abstracts across 8 types of cancer during the upcoming American...

/PRNewswire/ -- AbbVie (NYSE: ABBV) will present results from nearly 65 company and partner abstracts across 8 types of cancer during the upcoming American...

/PRNewswire/ -- Today, Johnson & Johnson MedTech* announced that DePuy Synthes, The Orthopaedics Company of Johnson & Johnson**, has secured 510(k) clearance...

Acute myocardial infarct (AMI) is a clinical emergency condition that encompasses STEMI and NSTEMI that leads to significant morbidity and mortality rate.

- Substantial Reductions in Key Hormones and Hormone Precursors Observed After 14 Days of Crinecerfont Treatment in Adolescents with Classic CAH- ...

Wide range of research across tumor types underscores Serviers commitment to discovering novel approaches to addressing difficult-to-treat cancers Phase 3...